{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-164018","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.321856+00:00","generated_at":"2026-05-15T05:22:59.777199+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FibroBiologics regains full compliance with Nasdaq listing requirements; monitoring periods imposed","bullets":["Nasdaq confirmed compliance with $2.5M stockholders' equity rule (Mar 9) and $1.00 bid price rule (Apr 17).","One-year Mandatory Panel Monitor for both equity and bid price; failure during monitor triggers delist determination without cure period.","Company remains listed on Nasdaq Capital Market under symbol FBLG; all prior listing matters closed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-164018","json":"https://secwatch.observer/filing/0001193125-26-164018.json","markdown":"https://secwatch.observer/filing/0001193125-26-164018.md","text":"https://secwatch.observer/filing/0001193125-26-164018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526164018/0001193125-26-164018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526164018/fblg-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:22:59.777199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}